Source: Annual Congress 2011 - Tuberculosis in immunocompromised hosts
Disease area: Respiratory infections

Abstract

Depression of TNF-a functions by its inhibitors not only suppresses the immune-inflammatory process, but also results in certain depression of an organism immune protection level and in increase in its susceptibility to TB. The medical and X-ray date of 263 patients taking INF for treatment of rhematoid disease were analyzed. The features of PT in patients taking INF were studied. All the patients every 6 months undergo X-ray examination of the lungs. The PT has developed in 8 patients taking INF and was diagnosed in 4,6±2,5 months of therapy, the number of infusions was from 2 to 6. The PT was diagnosed after respiratory complaints, in 5 patients the MBT was isolated from the sputum. Studying of Mantoux test with 2 TE before the INF course has shown that this method does not provide any reliable information, because all the patients before that have been taking immunosuppressive hormonal therapy for a long time. The x-ray archive analysis has not resulted in identification of any pathological changes. In case of detection of the disease in 5 patients there were visible multiple changes in both lungs, it was mostly changes in the upper lobes of the lungs. 3 patients with focal dissimination had infiltrates with small destruction cavities. All the patients had typical expressed bilateral enlargement of all groups of lymph nodes, tumor type with polycyclicity of the contours. The lymph nodes structure was normal. Rapid development of PT affection is typical for all the patients with tendency to generalisation and expressed hyperplasia of intrathoracic lymph nodes. In order to determine the risk of TB before administration of INF it is necessary to carry out quantiferon test and SCT.

Rating:

Share or cite this content

Citations should be made in the following way:
P. Gavrilov, V. Zhuravlev, L. Archacova, S. Dolgikh (Saint-Petersburg, Russian Federation). Pulmonary tuberculosis (PT) in patients taking the TNF-a inhibitor inflixinab (INF). Eur Respir J 2011; 38: Suppl. 55, 1948

Member's Comments

No comment yet.

Related content which might interest you: Effect of recombinant α-1 antitrypsin (rAAT) and TAPI on neutrophil elastase (NE) and matrix metalloproteinase-9 (MMP9) activity in induced sputum (IS) from healthy smokers and patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2003 - Progress on therapy for chronic obstructive pulmonary disease Year: 2003 Induced sputum (IS) angiogenic cytokines in patients with sarcoidosis (SA) Source: Eur Respir J 2005; 26: Suppl. 49, 268s Year: 2005 Primary resistance (PR) of mycobacterium tuberculosis (MBT) to antimicrobial drugs (AMBD) in patients (P) with destructive pulmonary tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 655s Year: 2004 Changes in the quantity of 1b-interleukin (IL-1b), tumor necrosis factor-a (TNF-a) and interferon-g (IF-g) in evaluation of the effectiveness of treatment of tuberculosis by DOTS Source: Eur Respir J 2004; 24: Suppl. 48, 486s Year: 2004 Liver function in patients with pulmonary tuberculosis (PT) before and during the initial phase of antituberculosis treatment (ATT) Source: Eur Respir J 2002; 20: Suppl. 38, 365s Year: 2002 Concentration of NO2-, a-acid protein (AAP), tumor necrotic factor (TNF-a), in the induced sputum of patients with bronchial asthma(BA) and chronic obstructive bronchitis (COB) Source: Eur Respir J 2001; 18: Suppl. 33, 367s Year: 2001 Aerosol delivery of an immunomodulator (interferon-γ 1b) within mouse lungs Source: International Congress 2015 – Interstitial lung diseases I Year: 2015 Polymorphism of multidrug resistance gene (MDR1), interleukin 4 (IL4), IL13 genes in asthmatic patients and patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2008 - Advances in functional genomics of neoplastic and non-neoplastic lung diseases Year: 2008 Matrix metalloproteinases (MMPs) and acute phase proteins (APP) in predicting the efficacy of intensive phase treatment (IPP) in patients with pulmonary tuberculosis (PT) Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016 The effect of sputum processing on tumour necrosis factor (TNFα), secretory leukoprotease inhibitor (SLPI), interleukin-6 and leukotriene-B4 (LTB4) in chronic bronchitis and bronchiectasis Source: Eur Respir J 2001; 18: Suppl. 33, 364s Year: 2001 Aerosolized interferon-gamma (IFN-γ) in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2007 - Considerations in the therapeutic approach of interstitial lung disease: oxidative stress and inflammation Year: 2007 QuantiFERON-TB GOLD vs. TST methods of detection tuberculosis infection in rheumatoid arthritis patients with previously TNF α inhibitors treatment Source: Annual Congress 2011 - Tuberculosis in immunocompromised hosts Year: 2011 Effect of serum alpha-1-antitrypsin (AAT) and alpha-2-macroglobulin (AMG) levels on sputum conversion in active pulmonary tuberculosis Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis III Year: 2008 Surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with community acquired pneumonia (CAP) during the treatment program Source: International Congress 2014 – Clinical problems in acute and chronic lung diseases Year: 2014 Diagnostic value of tumour necrosis factor-α (TNF) in comparison to adenosine deaminase (ADA) in tuberculosis pleurisy Source: Eur Respir J 2001; 18: Suppl. 33, 499s Year: 2001 The use of phon resonant therapy (PRT) in treatment of patients with pulmonary tuberculosis, combined with infections, caused by chlamydia (C) and mycoplasma (M) Source: Eur Respir J 2004; 24: Suppl. 48, 52s Year: 2004 Relationship between interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-alpha), C-reaktive protein (CRP), albumin (ALB) and alkaline phosphatase (ALP) in bronchoalveolar lavage fluid (BALF) of patients with interstitial lung disease Source: Eur Respir J 2006; 28: Suppl. 50, 98s Year: 2006 Measurement of tumor necrosis factor (TNF)α, leukotriene B4 (LTB4), and interleukin 8 (IL8) in the exhaled breath condensate (EBC) in patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) Source: Eur Respir J 2007; 30: Suppl. 51, 584s Year: 2007 Re-activation of bovine tuberculosis in a patient treated with infliximab Source: Eur Respir J 2008; 32: 229-231 Year: 2008 Impact of bisphosphonate (BP) use on lung function decline and treatment response in patients (pts) with idiopathic pulmonary fibrosis (IPF) Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020